Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,139

If you are interested in superlongevity, I have a spectacular book for you: Lifespan — Why We Age and Why We Don’t Have To, by David Sinclair PhD.

Sinclair has written a book about all the various ways in which humans can extend their lifespan and their healthspan.

One of the best aspects of this book is that Sinclair has a way of writing that is clear and insightful. It is so rare for me to read a book about scientific experiments in which it is easy to follow the methodology, but it is unique to also have an explanation of the application of the results that is crystal clear. Sinclair does both simply and easily.

Sinclair writes about all of the avenues that I’ve heard of for life extension. Metformin. NAD+. NMN. NR. Diet. Exercise. Resveratrol. Senolytics.

However, the most gripping aspect of this book is Sinclair’s Information Theory of Aging. Here is one excerpt from the book:

“…epigenetic noise causes the same kind of chaos. It is driven in large part by highly disruptive insults to the cell such as broken DNA…And this, according to the Information Theory of Aging is why we age. It’s why our hair grays. It’s why our skin wrinkles. It’s why our joints begin to ache. Moreover, it’s why each one of the hallmarks of aging occurs, from stem cell exhaustion and cellular senescence to mitochondrial dysfunction and rapid telomere shortening.”

Now, I have to admit that I know absolutely nothing about epigenetics. But if it could be this crucial to superlongevity, you better believe I’m going to start learning about epigenetics! And Sinclair does a good job of explaining how epigenetics is crucial in the aging process.

Continue reading “Lifespan: Why We Age—and Why We Don’t Have To” | >

The Pennsylvania-based biotechnology company said early Thursday that it was awarded a grant of up to $9 million by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the new strain of coronavirus, 2019-nCoV, which originated in Wuhan, China, and has killed no less than 17 people.

Kim said after the DNA sequence of the new coronavirus strain was made publicly available on Jan. 11, Inovio was able to design and construct a potential vaccine in “a matter of hours,” and the animal-testing process has already begun.

As the coronavirus out of China spreads and gets deadlierof health care companies that announce plans to take part in finding a vaccine, or identifying patients with the new strain, have rallied sharply in very active trading.

On Thursday, among the bigger coronavirus gainers was Inovio Pharmaceuticals Inc.’s stock INO +10.42%, which ran up 12% to the highest close since May 9. Trading volume swelled to 12.3 million shares, compared with the full-day average over the past 30 days of about 1.4 million shares, according to FactSet.

Read more | >

The first person diagnosed with the Wuhan coronavirus in the United States is being treated by a few medical workers and a robot.

The robot, equipped with a stethoscope, is helping doctors take the man’s vitals and communicate with him through a large screen, said Dr. George Diaz, chief of the infectious disease division at the Providence Regional Medical Center in Everett, Washington.

Read more | >

An #Israeli startup is hoping to help stop the spread of the deadly #coronavirus by shipping meters of anti-pathogen fabric to produce face masks or other protective clothing to #China.

“We see an epidemic,” said Liat Goldhammer-Steinberg, CTO of Sonovia Ltd., an Israeli company whose technology is based on a lab scale sonochemical process that was developed at Bar-Ilan University. “We have the ability to help prevent the virus from spreading.”

Read more | >

From January 23

Gilead Sciences Inc said on Thursday it was assessing whether its experimental Ebola treatment could be used against the new coronavirus that has sickened hundreds of people in China and led to at least 18 deaths. “Gilead is in active discussions with researchers and clinicians in the United States and China regarding the ongoing Wuhan coronavirus outbreak and the potential use of remdesivir as an investigational treatment,” a company spokesman said in an emailed statement.

(Reuters) — Gilead Sciences Inc said on Thursday it was assessing whether its experimental Ebola treatment could be used against the new coronavirus that has sickened hundreds of people in China and led to at least 18 deaths.

“Gilead is in active discussions with researchers and clinicians in the United States and China regarding the ongoing Wuhan coronavirus outbreak and the potential use of remdesivir as an investigational treatment,” a company spokesman said in an emailed statement.

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID) told Reuters his agency was working with Gilead to test the company’s antiviral drug in people infected with the new coronavirus.

Read more | >

The deadly animal-borne coronavirus spreading globally may have originated in a laboratory in the city of Wuhan linked to China’s covert biological weapons program, said an Israeli biological warfare analyst.

Radio Free Asia last week rebroadcast a Wuhan television report from 2015 showing China’s most advanced virus research laboratory, known the Wuhan Institute of Virology. The laboratory is the only declared site in China capable of working with deadly viruses.

Read more | >

The first case of novel coronavirus was confirmed in Orange County Saturday, health officials said.

The Orange County Health Care Agency’s Communicable Disease Control Division, which received confirmation from the Centers for Disease Control and Prevention, said the infected person is a traveler from Wuhan, China.

The respiratory disease has sickened 1,975 people and killed 56, almost all in Wuhan.

Read more | >

Sorry, might be a re-post, new source (r;ns)

Fighting cancer can sometimes feel like a game of Whack-A-Mole – even after a primary tumor is removed the disease can crop up again in other organs. Now, researchers at the Harry Perkins Institute of Medical Research have developed a drug that can prevent cancer from spreading.

Previous research has shown that before tumors start to spread, they secrete substances that prepare new places for them to settle down. One way in which the disease does this is by making blood vessels in the area “leaky,” allowing the cancer to penetrate them easier. And it’s this process that the new drug, created by researchers at the Harry Perkins Institute, prevents.

“While this behavior of cancer was already known, what we have discovered is that we can interfere with this process because of the way this new drug affects blood vessels,” says Ruth Ganss, an author of the study. “We’ve discovered it restores the leaky vessels which results in the cancer cells flowing past and not setting up shop.”

Read more | >

Medical science has been this optimistic before about finding a cure for Alzheimer’s, but in most cases the scientists, patients and their families have suffered serious disappointment. The bitter truth is that over 99 percent of all clinical trials for Alzheimer’s treatments end in failure. For now it is not only incurable, but a major mystery and irreversible. The chemical basis for the disease is still unclear. The research is directed in many directions and based on very different assumptions and approaches.

One focus in recent years is based on the “amyloid assumption,” which says the amyloid beta peptide plays a major role in the development of the disease. The accumulation of the “sticky” amyloid protein plaques is responsible for the damage, by building up into clumps that can cause inflammation in the brain and the death of neurons. These plaques are the main target of most Alzheimer’s research today. Almost 90 percent of the scientific resources in Alzheimer’s research are devoted to developing drugs and treatments to reduce the concentrations and activity of amyloid beta in the brain.

Read more | >